{
    "nctId": "NCT05641246",
    "briefTitle": "Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine",
    "officialTitle": "Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.",
    "overallStatus": "COMPLETED",
    "conditions": "Hand and Foot Syndrome",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 86,
    "primaryOutcomeMeasure": "\u2022 Incidence of HFS between control arm (Urea-based cream (CARBAMIDE\u00ae)) and intervention arm (Combination of Urea-based cream (CARBAMIDE\u00ae) and (VOLTAREN\u00ae) Emulgel 1%) measured by (CTCAE v 5.0).",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Adults aged 18 years and above.\n2. Females.\n3. Histologically proven breast cancer patients receiving Capecitabine (XELODA \u00ae) chemotherapy.\n4. life expectancy greater than 18 weeks.\n\nExclusion Criteria:\n\n1. Hypersensitivity to diclofenac, aspirin or other non-steroidal anti-inflammatory drugs (NSAIDS).\n2. History of Urticaria.\n3. History of acute rhinitis\n4. Asthmatic Patients.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}